Brief: Rani Therapeutics Announces Positive Topline Results From Phase 1 Study Of Rt-102 In Osteoporosis
10/08/2022 21:27
Aug 10 (Reuters) - Rani Therapeutics Holdings Inc RANI.O :
* RANI THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM
PHASE
1 STUDY OF RT-102 IN OSTEOPOROSIS
* RANI THERAPEUTICS HOLDINGS INC - RT-102 WAS GENERALLY
WELL-TOLERATED, WITH NO RANIPILL™-RELATED ADVERSE EVENTS
* RANI THERAPEUTICS - BIOAVAILABILITY OF PTH DELIVERED VIA
RANIPILL WAS FOUND TO BE 300-400% GREATER THAN PTH DELIVERED VIA
SUBCUTANEOUS INJECTION
* RANI THERAPEUTICS HOLDINGS INC - IMPROVED RANIPILL DESIGN
ENABLED 95% DRUG DELIVERY SUCCESS RATE
Source text for Eikon: ID:nGNXN29fH
Further company coverage: RANI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rani Therapeutics Holdings
See all newsRani Therapeutics Q2 net loss narrows as revenue rises helped by Chugai agreement
Brief: Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Pegbio Co Enters MoU With Rani Therapeutics
Brief: Rani Therapeutics Announces R&D Collaboration With PegBio
Rani Therapeutics Q1 contract revenue rises on Chugai collaboration; announces CFO transition